BIOCOM for BIOCOM
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Advocated for changes to the drug pricing provisions of the Inflation Reduction Act Advocated for the adoption of a Transitional Coverage for Emerging Technologies payment pathway for medical devices. Advocated for policies that advance the use of emerging technologies, including AI in health care Advocated for reauthorization of the Rare Pediatric Disease Priority Review Voucher program
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURE FABREGA CLARK | — |
| MEGAN ELIZABETH KASTNER New | — |
Copyright/Patent/Trademark CPT
Advocated for the protection of Intellectual Property rights Expressed opposition to FDA and PTO activities that would undermine IP rights. Advocated against policies that would negatively impact technology transfer programs at universities Advocated in support of less restrictive merger & acquisition policies in life sciences Advocated for granting injunctions with respect to infringing conduct once a court enters a final judgement against an infringer.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MEGAN ELIZABETH KASTNER New | — |
Trade (domestic/foreign) TRD
Advocated for strengthening the US supply chain and mitigating supply chain disruptions of essential products Advocated for a strong and diverse global supply chain Advocated on the difficulties of onshoring too quickly and expressed the desire to, but through proper channels Advocated against steep tariffs on pharmaceuticals, APIs, and med devices Responded to OSTP RFI on strengthening America's global competitiveness
| Lobbyist | Covered position, as disclosed |
|---|---|
| MEGAN ELIZABETH KASTNER New | — |
Budget/Appropriations BUD
Advocated for increased discretionary funding for HHS appropriations, including NIH, CDC, BARDA, SNS, CCBHC Advocated for increased discretionary funding for FDA appropriations Advocated for increased discretionary funding for all federally funded scientific research institutions Advocated for reauthorization of SBIR/STTR programs
| Lobbyist | Covered position, as disclosed |
|---|---|
| MEGAN ELIZABETH KASTNER New | — |
Economics/Economic Development ECN
Advocated for SBIR/STTR reauthorization Discussed and informed on the Biocom CA 2025 Life Science Economic Impact Report
| Lobbyist | Covered position, as disclosed |
|---|---|
| MEGAN ELIZABETH KASTNER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.